The efficacy of mGluR5 antagonists has been reported in trials with patients with gastroesophageal reflux; however, data from patients with Parkinson’s disease or FXS have not been as robust as hoped (Witkin et al., 2022). Here, GRM5 is linked to gastroesophageal reflux disease.